NCT00425035View on ClinicalTrials.gov

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

February 28, 2003

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

Panitumumab (ABX-EGF)

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY